ArticleDrug safety2026
Drugs Withdrawn from the Canadian Market for Safety and Effectiveness Reasons, 1990-2024: A Cross-Sectional Study.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAt times it is necessary to withdraw drugs after they have been approved because of lack of effectiveness or safety concerns. Health Canada does not keep a list of withdrawn drugs.
objectiveThe aim of this study was to generate a list of all drugs approved since 1990 and subsequently withdrawn from the Canadian market for safety or effectiveness reasons until the end of 2024. This list was used to examine trends in the number of withdrawals and the percent of new drugs that are approved but eventually withdrawn.
methodsA list of withdrawn drugs was developed based on previous published research and supplemented by examining lists of withdrawn drugs in other jurisdictions. The time, in years, was calculated between the date of approval and withdrawal. The reasons for withdrawal came from either Health Canada documents or, if unavailable, from international sources. Withdrawals for commercial reasons were not included in the analysis.
resultsOf the 1094 drugs approved from January 1, 1990, to December 31, 2024, a total of 37 were withdrawn: 32 were new active substances (molecules never marketed before in any form) and five were other types of new drugs. The median time to withdrawal was 3.60 years (interquartile range 2.45-9.50). Approximately 5% of all new active substances approved in a 5-year period were eventually withdrawn over the period 1990-2009. Between 2010 and 2019, the withdrawal rate was < 2%. The most common reasons for withdrawal were cardiac and liver complications.
conclusionAs a percent of all drugs approved, relatively few drugs are withdrawn, and the number of drug withdrawals as a percent of approvals declined between 2010 and 2019.
Indexed as
Identifiers
40931269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.